Help patients and clinicians fight for their right to psilocybin

Help TheraPsil-Supported Patients and Clinicians Fight for Legal Psilocybin

Our friends at TheraPsil helped 86 clinicians apply for Section 56 exemptions so they could participate in a psilocybin therapy training program.

Unfortunately, Health Canada denied the clinicians access to psilocybin, which will impact over 1500 patients who are desperately awaiting psilocybin treatments. Many Canadians will die before they have the chance to try psilocybin therapy.

TheraPsil needs our help to raise $100K to take the Canadian government to court to achieve lasting policy change so that Canadians can access the treatment before it’s too late. 

Support the cause here.


Lexston Life Sciences Is Granted Section 56 Exemption From Health Canada and Embarks on the Development of Portable Technology for Quantification and Traceability of Psilocybe Mushrooms

Lexston Life Sciences Is Granted Section 56 Exemption From Health Canada and Embarks on the Development of Portable Technology for Quantification and Traceability of Psilocybe Mushrooms

Lexston Life Sciences (LEXT) received a Section 56 exemption to research psilocybin. It is developing a tool that can rapidly identify and quantify different mushroom compounds such as psilocin, psilocybin, baeocystin, norbaeocystin and aeruginascin.

Psychedelic therapy just got A LOT more accessible for Canadians

BREAKING: Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA

Until now, the only way for patients to access psychedelic therapy outside a clinical trial was to apply for a Section 56 exemption and wait months on end to (possibly) receive approval from Health Canada.

Despite six more patients receiving the exemption over the holidays, the system remains flawed.

Thankfully, this Wednesday, Health Canada made an amendment to this thing called the Special Access Program (SAP), which enables healthcare practitioners to request access to drugs that are not yet approved, but have shown promise in clinical trials.

The amendment allows practitioners to request access to psilocybin and MDMA for their patients with serious, life-threatening, or treatment-adverse conditions. And the best part: requests are typically processed in just 1 day! 🎉

While this does not guarantee access for patients, it certainly feels like a big step in the right direction.

To learn more about the amendment, check out TheraPsil’s free webinar on Jan. 19th.

PDF of article


You no longer have to be on your deathbed to eat mushrooms!

Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms

Up until this week, the only people in Canada that could legally access psilocybin therapy were patients with terminal illnesses. 

Things changed on Monday, when the non-profit organization TheraPsil helped three Canadians with mental health issues get Section 56 exemptions, granting them access to psilocybin therapy.

“This is a very clear indication that exemptions are now available for people who have anxiety, depression, addiction, and chronic pain,” says TheraPsil’s CEO. “It opens it up to everyone.”

PDF of article

Taking Health Canada to court

Health Canada dragging feet on approving magic mushrooms for therapeutic use, patients and advocates say

To date, Health Canada has granted legal exemptions to 19 healthcare professionals and 32 terminally-ill patients so they can legally use psilocybin in clinical settings. The patients have reported life-changing results, yet at least 119 patients are still awaiting exemptions to gain access to the therapy, and experts are beginning to see the lengthy process as an ethical issue.

TheraPsil, a Victoria non-profit, has hired lawyers to take action against Health Canada and Health Minister Patty Hajdu through the federal court. TheraPsil’s efforts will hopefully speed up the application process and bring justice to patients who are desperate for psilocybin therapy.



16 healthcare professionals granted access to psilocybin

Canadian Government Agency Removes Barrier for Psilocybin Therapy

Health Canada removed a barrier for psilocybin research by allowing 16 health-care professionals to legally possess and consume psilocybin-containing mushrooms in clinical settings, the same exemptions previously given to more than a dozen terminally-ill patients. TheraPsil, a Victoria non-profit that aims to treat mental health issues with psilocybin, celebrates these exemptions, as they could lead to important new medical applications in the mental health sector.

PDF of article